Reviewing Digirad (DRAD) & Its Rivals
Digirad (NASDAQ: DRAD) is one of 77 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Digirad to related companies based on the strength of its dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
This table compares Digirad and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Digirad and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Digirad||$125.47 million||$14.30 million||-3.88|
|Digirad Competitors||$2.14 billion||$234.27 million||-82.83|
Digirad’s peers have higher revenue and earnings than Digirad. Digirad is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Digirad pays an annual dividend of $0.22 per share and has a dividend yield of 9.8%. Digirad pays out -37.9% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 25.9% of their earnings in the form of a dividend. Digirad is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.
Institutional and Insider Ownership
53.1% of Digirad shares are owned by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 11.9% of Digirad shares are owned by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for Digirad and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Digirad currently has a consensus target price of $6.00, suggesting a potential upside of 166.67%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 0.52%. Given Digirad’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Digirad is more favorable than its peers.
Risk & Volatility
Digirad has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Digirad’s peers have a beta of 0.96, meaning that their average share price is 4% less volatile than the S&P 500.
Digirad beats its peers on 11 of the 15 factors compared.
Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center. Through Mobile Healthcare segment, the Company provides contract sales services and diagnostic imaging services. Through Diagnostic Imaging segment, the Company sells its internally developed solid-state gamma camera imaging systems and camera maintenance contracts. Through Medical Device Sales and Services segment, the Company provides contract sales services, as well as warranty and post-warranty services, under contract with Philips Healthcare within a defined region in the upper Midwest region of the United States.
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.